Navigation Links
A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients

nts received G1 doses of 30ug/kg/day, while E1 doses started at 0.3ug/kg/day for most patients with some patients escalating to E1 doses of 0.5ug/kg/day or reducing to 0.2ug/kg/day. In the trial, 30 type 2 diabetes patients on oral anti-diabetic agents (metformin with/without TZD) were enrolled. These patients continued on their oral anti-diabetic medication for the duration of the trial. Upon entry into the trial, the patients' HbA1c levels ranged between 6.8% and 10.9%, with a mean HbA1c level of 8.1%. Transition reported interim unblinded data from this study in a press release dated March 5th, 2007.

About Transition

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include regenerative therapies E1-I.N.T.(TM) and GLP1-I.N.T.(TM) for the treatment of diabetes and AZD-103/ELND-005 for the treatment of Alzheimer's disease. Transition has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine. Transition's shares are listed on the Toronto Stock Exchange under the symbol "TTH". For additional information about the company, please visit www.transitiontherapeutics.com.

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including funding and conducting clinical trials. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
7. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
8. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
9. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
10. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
11. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
Post Your Comments:
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire-iReach/ -- CountryFocus: Healthcare, ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ... Healthcare, Regulatory and Reimbursement Landscape Poland " an ... trends in the healthcare market and provides insights ... infrastructure. Most importantly, the report provides valuable insights ...
(Date:8/28/2014)... BURLINGTON, Mass. , Aug. 28, 2014  Decision Resources ... will remain constant, at around $7.7 billion by 2023 in ... , Germany , Italy ... United Kingdom and Japan . ... KGaA,s Erbitux will be balanced out by the launch of ...
(Date:8/28/2014)...   Edison Nation Medical , the premier ... for product ideas to improve the health and ... through the 6-month search ( www.EdisonNationMedical.com/Seniors ) will ... healthcare retailers with whom Edison Nation Medical has ... 65 and older. The objective of ...
Breaking Medicine Technology:Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 2Edison Nation Medical Launches Open Innovation Search to Uncover Innovative Senior Care Products 3
... RIDGE, N.J. , March 15 Regado Biosciences, ... aptamers with active control agents, announced that Chris Rusconi ... Steven Zelenkofske , DO, FACC, Senior Vice President , Chief ... Cardiology on Monday, March 15, 2010 in ...
... SAN FRANCISCO, Calif. , March 15 Poniard ... on innovative oncology therapies, today announced the sale of 4,229,000 ... Fund, Ltd. for gross proceeds of approximately $6.3 million ... existing committed equity financing facility with Commerce Court.  Poniard intends ...
Cached Medicine Technology:Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 2Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 3Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010 4Poniard Pharmaceuticals Announces $6.3 Million Financing 2Poniard Pharmaceuticals Announces $6.3 Million Financing 3Poniard Pharmaceuticals Announces $6.3 Million Financing 4
(Date:8/29/2014)... The 8th Annual Paint Columbus Pink® is a series ... Pooch Contest, Light of Life Ceremony, Power in Prayer, Bright ... – all in support of cancer awareness. , Paint Columbus ... Columbus Pink Foam and Obstacle Challenge on Saturday, October 4th, ... Columbus, Georgia 31904. It will be the first foam and ...
(Date:8/29/2014)... Canada Older adults who stay active by volunteering ... altruistic feeling they are receiving a health boost! ... Rotman Research Institute at Baycrest Health Sciences and published ... the first to take a broad-brush look at all ... of formal volunteering for older adults. , Lead investigator ...
(Date:8/29/2014)... After having a double mastectomy due ... have breast reconstruction. She found that the look of ... that there needed to be a solution. , The ... or man who needs or wants breast improvements. It's ... and peace of mind. Producible in design variations, the ...
(Date:8/29/2014)... August 29, 2014 Honey Gifts, premium ... company will now be selling purse-sized adult toys and ... way that they can be carried in a woman’s ... the purse-sized range at Honey Gifts is also leak-free ... life and rechargeable batteries are common characteristics of Honey ...
(Date:8/29/2014)... 2014 University of Western States (UWS), ... announced that Daniel Redwood, DC, director of the human ... the Year,” by the Missouri State Chiropractors Association (MSCA) ... , Patrick Montgomery, DC, president of the MSCA, cited ... Missouri House Task Force for Medicaid Reform, in bringing ...
Breaking Medicine News(10 mins):Health News:Paint Columbus Pink Cancer Awareness/Kick-Off Meeting for Anyone Interested in Participating 2Health News:Evidence mounting that older adults who volunteer are happier, healthier 2Health News:Honey Gifts Now Provides Purse Sized Adult Toys in Vancouver 2Health News:University of Western States Director of Human Nutrition and Functional Medicine Daniel Redwood, DC, named Missouri Educator of the Year by MSCA 2
... Dec. 1 America,s pharmaceutical research companies are testing ... related conditions, according to a report released today by the ... marks the 20th anniversary of "World AIDS Day" - a ... of Ministers of Health on Programmes for AIDS Prevention. , ...
... Early discussion with your orthopaedic surgeon is the driving force ... , ROSEMONT, Ill., Dec. 1 /PRNewswire-USNewswire/ ... any musculoskeletal injury may be anxious to get back into ... the wheel of a car can be a difficult and ...
... Deadline Is December 31st , , ... D annual enrollment period is nearly halfway over - running from ... is an opportunity for seniors to change the prescription drug program ... in a Part D plan to enroll. , ...
... Unmet Needs for HIV Prevention, Calls on Governments to Increase ... (Para tener acceso a una copia completa de ... , , WASHINGTON, Dec. 1 ... women and Latina women in the United States is demanding ...
... 1, 2008 -- 11 a.m. news event -- Hall of ... DC 20001 , , WASHINGTON, ... coming together to outline the current fiscal situation states are ... a recovery package that will spur job growth, support infrastructure ...
... DISCOVERY IN MOLECULAR IMAGING , , ... North America (RSNA) honored Ralph Weissleder, MD, PhD, with its ... one scientist who has made original significant contributions to the ... is Professor at Harvard Medical School , as well ...
Cached Medicine News:Health News:109 Medicines and Vaccines Now in Development for HIV/AIDS 2Health News:109 Medicines and Vaccines Now in Development for HIV/AIDS 3Health News:When to Get Back Behind the Wheel While on the Road to Recovery 2Health News:When to Get Back Behind the Wheel While on the Road to Recovery 3Health News:Radio Interview Opportunity: Important News for Seniors 2Health News:Latin American and U.S. Latina Women Unite to Demand Access to the Female Condom 2Health News:Latin American and U.S. Latina Women Unite to Demand Access to the Female Condom 3Health News:Governors, Legislators Update Current State Fiscal Conditions, Push for Economic Recovery Package from Congress, President-elect 2Health News:VisEn Co-Founder Named Radiologic Society's 'Outstanding Researcher of the Year' 2Health News:VisEn Co-Founder Named Radiologic Society's 'Outstanding Researcher of the Year' 3
... RPR kits use carbon particles coated ... which will combine with antibody present ... particles are suspended in a medium ... specific reactions. Positive reactions are shown ...
... The BD Macro-Vue RPR (Rapid ... and Tear-drop Tests are nontreponemal testing ... syphilis described in A Manual of ... in this manual are the most ...
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
For use as a quality assurance reagent in assays detecting IgG antibody to mumps virus (mumps IgG), IgG antibody to measles (Rubeola) virus (measles IgG) and IgG antibody to varicella zoster virus (V...
Medicine Products: